Baxter Phillips
Director de Operaciones en LOBE SCIENCES LTD. .
Fortuna: 10 880 $ al 30/04/2024
Perfil
Baxter F.
Phillips is currently serving as an Independent Director at Cambridge Allergy Ltd., as the Chief Operating Officer & Director at Lobe Sciences Ltd., and as the President of Altemia & Co. LLC.
Previously, he held the position of President & Chief Executive Officer at Neurogastrx, Inc. from 2015 to 2017, Chief Business Officer at AmpliPhi Biosciences Corp.
from 2014 to 2015, and Head-Investor Relations at Osteologix Holdings Plc from 2010 to 2011.
Mr. Phillips obtained his undergraduate degree from Hampden-Sydney College and his MBA from the Mason School of Business of The College of William & Mary.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
LOBE SCIENCES LTD
0.87% | 30/06/2023 | 680 000 ( 0.87% ) | 10 880 $ | 30/04/2024 |
Cargos activos de Baxter Phillips
| Empresas | Cargo | Inicio |
|---|---|---|
| LOBE SCIENCES LTD. | Director de Operaciones | 07/06/2023 |
Cambridge Allergy Ltd.
 Cambridge Allergy Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Allergy Ltd. operates as a biopharmaceutical company which manufactures medicines for food allergies. The company was founded by Sherden Timmins, Andrew Clark, and Pamela Ewan on December 7, 2015 and is headquartered in Cambridge, the United Kingdom. | Director/Miembro de la Junta | 16/10/2018 |
Altemia & Co. LLC
 Altemia & Co. LLC Pharmaceuticals: OtherHealth Technology Part of Lobe Sciences Ltd., Altemia & Co. LLC is a medical food company. The company is based in Stuart, FL. Altemia & Co. was acquired by Lobe Sciences Ltd. on April 29, 2024 for $1.01 million. | Presidente | - |
Antiguos cargos conocidos de Baxter Phillips.
| Empresas | Cargo | Fin |
|---|---|---|
Neurogastrx, Inc.
 Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | Director Ejecutivo | 01/10/2017 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Contacto de Relaciones con Inversores | 27/05/2015 |
| OSTEOLOGIX HOLDINGS PLC | Public Communications Contact | 01/08/2011 |
Formación de Baxter Phillips.
| Hampden-Sydney College | Undergraduate Degree |
| Mason School of Business of The College of William & Mary | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| LOBE SCIENCES LTD. | Process Industries |
| Empresas privadas | 5 |
|---|---|
Osteologix Holdings Plc
 Osteologix Holdings Plc Pharmaceuticals: OtherHealth Technology Osteologix Holdings Plc engaged in the development of innovative pharmaceuticals for the treatment and prevention of bone and joint tissues diseases. The company was founded in October 2004 and was headquartered in Dublin, Ireland. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | Health Technology |
Cambridge Allergy Ltd.
Cambridge Allergy Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Allergy Ltd. operates as a biopharmaceutical company which manufactures medicines for food allergies. The company was founded by Sherden Timmins, Andrew Clark, and Pamela Ewan on December 7, 2015 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Altemia & Co. LLC
Altemia & Co. LLC Pharmaceuticals: OtherHealth Technology Part of Lobe Sciences Ltd., Altemia & Co. LLC is a medical food company. The company is based in Stuart, FL. Altemia & Co. was acquired by Lobe Sciences Ltd. on April 29, 2024 for $1.01 million. | Health Technology |
- Bolsa de valores
- Insiders
- Baxter Phillips
